Inovio Pharmaceuticals is a biotechnology company focused on developing innovative therapies and vaccines for the treatment of serious diseases, particularly cancers and infectious diseases
Utilizing its proprietary DNA medicines platform, Inovio is engaged in creating synthetic DNA-based therapies that aim to trigger an immune response in the body to fight off disease. The company is dedicated to advancing its product candidates through various phases of clinical trials, and it collaborates with various organizations and institutions to enhance its research and development efforts, ultimately striving to address unmet medical needs and improve patient outcomes.
Shares of Inovio Pharmaceuticals pulled back by 5.3% during Wednesday's session. The decline may be attributed to profit-taking, as investors assess renewed focus on respiratory illnesses.
Inovio Pharmaceuticals shares are trading higher by 20.7% Tuesday afternoon. Vaccine stocks are rising amid growing concerns about respiratory illnesses.
Inovio Pharmaceuticals shares are trading lower by 38% during Friday's session. The company priced a public offering of 10 million shares of common stock and accompanying warrants.
INO stock results show that Inovio Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Stephens covers INOVIO Pharmaceuticals highlighting its diverse clinical pipeline and FDA's consideration of INO-3107 Phase 1/2 trials for Accelerated Approval. Potential as the first non-surgical RRP treatment.
